Special COVID-19 ECHO session #31 on 30 October!

Manufacturers of COVID-19 Rapid Diagnostics Tests:LumiraDx SARS-CoV-2 Antigen Assay
 Join ASLM and LabCoP this Friday, 30 October 2020 at 16:00 East Africa Time for a special session where we focus on the LumiraDx SARS-CoV-2 Antigen Assay.

The global partnership to launch the secure availability of antigen rapid tests was recently announced by WHO, The Global Fund, Unitaid, Africa CDC, FIND and other partners. The aim of this partnership is to ensure that low-priced, high-quality antigen rapid tests are made available internationally in order to avoid the test shortages experienced since the start of the pandemic. Antigen tests provide a lower cost and more flexible way to deploy testing programs in health facilities, in communities, for vulnerable populations and other settings for effective epidemic control. In this session, participants will learn about the following:  Details about the LumiraDx antigen test platform and how it works Status regarding regulatory approval Performance, run time and other technical considerations Requirements/consumables not supplied with the test(s) How antigen tests can be deployed to support testing programmes for COVID-19 epidemic disease control 

Presenter:Dr Nigel Lindner, Chief Technology Officer, LumiraDx

 Register for the session here. 

Please note that we are now requiring a passcode to enter each session. When prompted, please enter passcode: 822231 

Zoom Details:https://us02web.zoom.us/j/89243423018?pwd=MU1MM0xZUGNIU2dMSktDR2ZEaXJOZz09 

Meeting ID: 892 4342 3018Passcode: 822231

One tap mobile+16465588656,,89243423018# US (New York)+16699009128,,89243423018# US (San Jose) Dial by your location+1 646 558 8656 US (New York)+1 669 900 9128 US (San Jose)+1 253 215 8782 US (Tacoma)+1 301 715 8592 US (Germantown)+1 312 626 6799 US (Chicago)+1 346 248 7799 US (Houston)Meeting ID: 892 4342 3018

Find your local number: https://us02web.zoom.us/u/kAQIebc1O
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *